Ryvu Therapeutics S.A. (FRA:9Y4)

Market Cap	153.61M
Revenue (ttm)	21.19M
Net Income (ttm)	-27.82M
Shares Out	n/a
EPS (ttm)	-1.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	5.57
Previous Close	5.72
Day's Range	5.57 - 5.57
52-Week Range	4.17 - 11.86
Beta	n/a
RSI	64.34
Earnings Date	Nov 20, 2025

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 328
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9Y4

Financial Performance

In 2024, Ryvu Therapeutics's revenue was 101.96 million, an increase of 51.51% compared to the previous year's 67.30 million. Losses were -111.44 million, 21.0% more than in 2023.

Financial numbers in PLN